Systemic complications of Aicardi Goutières syndrome using real-world data
Isabella Peixoto de Barcelos(Children's Hospital of Philadelphia), Laura Adang(Children's Hospital of Philadelphia), Russell D’Aiello(Children's Hospital of Philadelphia), Adeline Vanderver(Children's Hospital of Philadelphia), David Isaacs(Vanderbilt University), Anjana Sevagamoorthy(Children's Hospital of Philadelphia), Florian Eichler(Harvard University), Sarah Woidill(Children's Hospital of Philadelphia), Stephanie Keller(Children's Healthcare of Atlanta), Francesco Gavazzi(Children's Hospital of Philadelphia), Keith Van Haren(Stanford University), Jamie L. Fraser(Children's National), Nicholson Modesti(Children's Hospital of Philadelphia), Lisa Emrick(Baylor College of Medicine), Amy Pizzino(Children's Hospital of Philadelphia), Lauren Charlton(Children's Hospital of Philadelphia), Amanda Jan(Children's Hospital of Philadelphia), Johanna Schmidt(Counseling Center), Justine Shults(Children's Hospital of Philadelphia)
Cited by 8
Related Papers
Characterization of human disease phenotypes associated with mutations in <i>TREX1</i>, <i>RNASEH2A</i>, <i>RNASEH2B</i>, <i>RNASEH2C</i>, <i>SAMHD1</i>, <i>ADAR</i>, and <i>IFIH1</i>
|American Journal of Medical Genetics Part A|2015|617
Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy
|New England Journal of Medicine|2017|592
Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
|The Lancet Neurology|2013|441